2024年11月7日，Moderna公司打破了市场预期，公布了其2024年第三季度财报，收入达到19亿美元，较去年同期增长3.5%。这一业绩的背后，除了组织运营的成功管理，更重要的是其新冠疫苗Spikevax的出色表现。然而，尽管在财报中取得了意外的成功，这份喜悦却伴随着不可忽视的警示和市场竞争的压力。 全球新冠疫苗市场的现状 自COVID-19疫情开始以来，新冠疫苗市场经历了迅猛的发展。在这一领 ...

当全球还在为新冠疫情的阴影逐渐消散而松一口气时，一场新的战斗却悄然打响。美国西北大学在特拉华州联邦法院对Moderna提起了一项新的专利诉讼，指控该公司滥用其开发的脂质纳米颗粒（LNP）技术来制造Spikevax疫苗。这起诉讼不仅让人惊讶，更引发了广泛的关注。 根据起诉书，西北大学的研究人员早在2009年和2010年就率先使用LNP将mRNA递送到人类细胞中。该校声称，Moderna的Spikev ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

周四，TD Cowen将Moderna ...

Moderna Inc.

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

卫生部星期五（25日）发文告宣布，将在下星期一推出JN.1辉瑞／复必泰（JN.1 Pfizer-BioNTech／Comirnaty），以及JN.1莫德纳／Spikevax（JN.1 Moderna／Spikevax）这两款冠病疫苗。 根据全国免疫专家委员会的建议，这些更新版疫苗能够对当前和变种的冠病毒株产生更强的免疫 ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...